Close

Needham & Company Maintains a 'Hold' on Alexion Pharmaceuticals (ALXN); Hot Quarter and Fiery Fundamentals Along with Sizzling Valuation Jul 22, 2011 08:37AM
Needham & Company Maintains a 'Hold' on Alexion Pharmaceuticals (ALXN); Soliris Data at EHA Mtg Demonstrate Profound Treatment Effect Jun 13, 2011 07:58AM
Needham & Company Maintains a 'Hold' on Alexion Pharmaceuticals (ALXN); Soliris sBLA for aHUS Gets Priority Review – A Positive Yet Well Expected News Jun 1, 2011 10:49AM
Needham & Company Downgrades Alexion Pharmaceuticals (ALXN) to Hold; Solid Company with Strong Fundamentals, Yet Near-Term Growth/Other Positives Already Priced In Apr 25, 2011 07:53AM
Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference Apr 12, 2011 07:39AM


Feb 11, 2011 08:08AM Needham & Company Raises PT on Alexion Pharmaceuticals (ALXN) Based on Chocolate (Strong Soliris Growth in Current PNH Markets) AND Flowers (Soliris in New Markets, Faster aHUS Submission, Pipeline wi
Jan 5, 2011 07:55AM Needham & Company Reiterates a 'Buy' on Alexion Pharmaceuticals (ALXN); Soliris Growth Momentum Continues
Nov 22, 2010 08:12AM Needham & Company reiterates a 'Buy' on Alexion Pharmaceuticals (ALXN); Impressive Data at ASN Meeting Highlight the Potential of Soliris in aHUS
Sep 27, 2010 08:14AM Needham & Company Maintains a 'Buy' on Alexion Pharmaceuticals (ALXN), Adjusting Estimates for Soliris Sales Upwards
Apr 23, 2010 08:29AM Needham & Company Maintains a 'Buy' on Alexion Pharmaceuticals (ALXN); Early 2Q10 Preview Shows Continued Growth From Geographic Expansion
Jul 23, 2009 10:01AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)